Skip to content

Influence of Circulating Endothelial Progenitor Cells and Modifiable Vascular Risk Factors on Carotid Plaque Vulnerability

Influence of Circulating Endothelial Progenitor Cells and Modifiable Vascular Risk Factors on Carotid Plaque Vulnerability

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03218527
Acronym
IMPROVE
Enrollment
120
Registered
2017-07-14
Start date
2015-10-01
Completion date
2018-12-31
Last updated
2017-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Inflammation, Stroke

Brief summary

Ischemic stroke is a leading cause of death and disability worldwide. Atherosclerosis, responsible for the 20% of ischemic strokes, is characterized by lipid accumulation in the artery wall that leads to chronic inflammation, cell proliferation and ultimately to vessel stenosis. One of the main features related to plaque progression and vulnerability is inflammation. Positron emission tomography with 18-fluorodeoxyglucos (18-FDG PET) allows an accurate quantification of plaque inflammation and it has been proved its usefulness in predicting early stroke recurrences. The investigators aim to test how modifiable vascular risk factors influence plaque inflammation assessed by 18-FDG PET. In addition, investigators will assess the association of this inflammation and circulating endothelial progenitor cells

Interventions

None listed

Sponsors

Instituto de Salud Carlos III
CollaboratorOTHER_GOV
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ischemic stroke within 7 days before inclusion * At least one atherosclerotic plaque in the internal carotid artery * \>18 years old

Exclusion criteria

* Cardioembolic strokes according to TOAST criteria * Poor functional outcome (Rankin \>3) after stroke

Design outcomes

Primary

MeasureTime frameDescription
Change in the Standardized Uptake Value (SUV) of the internal carotid arteryBaseline and at one year follow-upInflammation change of the internal carotid artery assessed by the Standardized Uptake Value (SUV) obtained with 18FDG-PET scan at one-year follow-up
Change in the Target-to-Background Ratio (TBR) of the internal carotid arteryBaseline and at one year follow-upInflammation change of the internal carotid artery assessed by the Target-to-Background Ratio (TBR) obtained with 18FDG-PET scan at one-year follow-up
Change in the Endothelial Progenitor Cells CountBaseline and at one year follow-upChange in the Endothelial Progenitor Cells Count by flow cytometry

Countries

Spain

Contacts

Primary ContactPol Camps-Remom, MD
pcamps@santpau.cat+34660030907

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026